Dasabuvir
EXVIERA
What it isHCV NS5B non-nucleoside polymerase inhibitor; hepatitis C.
Why this oneIt added a third mechanism to early direct-acting combinations.
What limits itSuperseded by pangenotypic regimens. Hepatitis B reactivation; extensive CYP interactions from its ritonavir-boosted partners.
FDA-approved for
- chronic hepatitis C (2014)
NO BOXED WARNINGS
Principal riskSuperseded by pangenotypic regimens
Classes and tags
Clinical profile
Mechanism of action: Dasabuvir ballicule
